Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment Journal of Medicinal Chemistry You thought Ozempic was big? Just wait. The next generation of weight loss medications is already in clinical trials oral pills, monthly injections, and even triple action drugs that may work better than Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants Gabe 2024 Diabetes, Obesity and Metabolism Wiley Online Library Cagrilintide: The Next Gen Peptide for Weight Loss and Satiety Hubmed